Genetic Association of Monocyte Chemoattractant Protein 1 (MCP-1)-2518 Polymorphism in Mexican Patients With Transitional Cell Carcinoma of the Bladder

Urology

Volumn 74, Issue 2, 2009, Pages 414-418

  Vázquez Lavista, Luis Gabriel ^a   Lima, Guadalupe ^a   Gabilondo, Fernando ^a   Llorente, Luis ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RISK; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; ALLELES; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CHEMOKINE CCL2; CHEMOKINE CXCL12; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RECEPTORS, CCR2; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 67651120002     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.04.016     Document Type: Article

References (26)

1. Ross K.R., Yu M.C., and Yuan J.M. The epidemiology of bladder cancer. In: Vogelzang N. (Ed). Comprehensive Textbook of Genitourinary Oncology (2006), Lippincott Williams and Wilkins, Philadelphia, PA 357-363
2. Hemstreet G.P. Cytology of bladder cancer. In: Vogelzang N. (Ed). Comprehensive Textbook of Genitourinary Oncology (2000), Lippincott & Wilkins, Baltimore MD 322-332
3. Babjuk M., Oosterlinck W., Sylvester R., et al. EUA guidelines in non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 52 (2008) 303-314
4. Lerner S., Tangen C., Sucharew H., et al. Patterns of recurrence and outcomes following induction of bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. J Urol 177 (2007) 1727-1731
5. Vázquez-Lavista L.G., Flores-Balcázar C.H., and Llorente L. The bacillus Calmtte-Guérin as immunomodulator in bladder cancer. Rev Invest Clin 59 (2007) 146-152
6. Habuchi T., Marberger M., Droller M.J., et al. Prognostic markers in bladder cancer: international consensus panel on bladder tumor markers. Urology 66 (2005) 64-74
7. Hemstreet III G.P., Rao J., Hurst R.E., et al. Biomarkers in monitoring the efficacy of immunotherapy and chemoprevention of bladder cancer with dimethylsulfoxide. Cancer Detect Prev 23 (1999) 163-171
8. Watanabe E., Matsuyama H., Matsuda K., et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52 (2003) 481-486
9. Eto M., Koga H., Noma H., et al. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus Calmette-Guérin for superficial bladder tumors. Urol Int 75 (2005) 114-118
10. Leibovici D., Barton-Grossman H., Dinney C., et al. Polymorphisms in inflammation genes and bladder cancer: form initiation to recurrence, progression and survival. J Clin Oncol 23 (2005) 5746-5756
11. Basturk B., Yavascaoglu I., Oral B., et al. Cytokine gene polymorphisms can alter the effect of bacillus Calmtte-Guérin immunotherapy. Cytokines 35 (2006) 1-5
12. Luo Y., Chen X., and O'Donnell M.A. Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo. Clin Exp Immunol 147 (2007) 370-378
13. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
14. Rovin B.H., Lu L., and Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 259 (1999) 344-348
15. Winkler C., Modi W., Smith M.W., et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. Science 279 (1998) 389-393
16. Zafiropoulos A., Crikas N., Passam A.M., et al. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 41 (2004) e59
17. al S., Ollier W.E., and Hajeer A.H. A rare polymorphism at position -28 in the human RANTES promoter. Eur J Immunogenet 26 (1999) 373-374
18. Rovin B.H., Lu L., and Zhang X. A novel interleukin IL-8 polymorphism is associated with severe systemic lupus erythematosus nephritis. Kidney Int 62 (2002) 261-265
19. Dean M., Carrington M., Winkler C., et al., Hemophilia Growth and Development Study, Multicenter Aids Cohort Study, Multicenter Hemophilia Cohort Study San Francisco City, Alive Study. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273 (1996) 1856-1862
20. Shieh B., Liau Y.E., Hsieh P.S., et al. Influence of nucleotide polymorphism in CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 12 (2000) 1311-1318
21. Yang R., and Roden R. Genetic polymorphism and tumor immunotherapy. Curr Pharmacogenomics 1 (2003) 37-57
22. Salcedo R., Ponce M.L., Young H.A., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96 (2000) 34-40
23. Luther S.A., and Cyster J.G. Chemokines as regulators of T cell differentiation. Nat Immunol 2 (2001) 102-107
24. Sasayama S., Okada M., and Matsumori A. Chemokines and cardiovascular diseases. Cardiovasc Res 45 (2000) 267-269
25. Lebret T., Becette V., Barbagelatta M., et al. Correlation between p53 overexpression and response to BCG therapy in a high risk selected population of patients with T1G3 bladder cancer. J Urol 159 (1998) 788-791
26. Lebret T., Watson R.W., Molinié V., et al. HSP90 expression: a new predictive factor for BCG response in stage Ta-1 grade 3 bladder tumors. Eur Urol 51 (2007) 161-167